.jpg)
Course
Pharmacology and the ADMET Process
BIOL-40380
Understand the fundamentals of Pharmacology and the ADMET Process
The Pharmacology and the ADMET Process course provides a foundational understanding of the principles of pharmacology and the ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicology) of drugs. Students will learn about the mechanisms of drug action, drug targets, and how drugs interact with the body. Additionally, students will gain an understanding of the factors that influence the ADMET of drugs, including pharmacokinetics and pharmacodynamics. The course will also cover current topics in drug development and the regulatory process.Note: This new course is scheduled to launch in Summer 2025.
Topics
- Introduction to Pharmacology and ADME
- Pharmacokinetics: Absorption and Distribution
- Pharmacokinetics: Metabolism
- Pharmacokinetics: Elimination and Excretion
- Pharmacodynamics: Drug-Receptor Interactions
- Pharmacodynamics: Signal Transduction and Secondary Messengers
- Pharmacodynamics: Tolerance, Dependence, and Adverse Effects (Toxicology)
- Pharmacogenomics and Personalized Medicine
- Case Studies and Drug Development Applications
Learning Objectives
- Describe the steps in the pharmacology and ADMET process and their relevance in drug development
- Analyze pharmacology data including ADME properties, PKPD relationships, and toxicology findings
- Model human dose prediction based on analyses of pharmacology and toxicology data
- Make recommendations on pharmacology plans based on case studies
Prerequisites
Format
Course Information
Online
3.00 units
$845.00
Course sessions
Add To Cart
Add To Cart
Instructor:
Richard Myers has over 11 years of drug discovery experience within the pharmaceutical industry. Moving from large pharma to the startup world, Richard is currently a Pharmacology Consultant at three early pharmaceutical companies including Equillium Bio, Ferdia Therapeutics, and EverTree Bio. Looking long term, Richard is interested in entrepreneurship and launching a startup venture within the vibrant San Diego biotech hub.
Richard previously worked at Takeda Pharmaceuticals for 9 years within the Gastrointestinal and Inflammation Drug Discovery Unit, advancing novel drug ideas from target ID to clinical candidacy. Richard led multiple drug discovery projects including a small molecule ion channel agonist and a regenerative neuronal cell therapy. In addition to his globally facing project leadership role, Richard led a lab-based pharmacology team in San Diego that supported in vivo, in vitro, and histology studies across the GI & Inflammation portfolio.
Richard earned his Ph.D. in Molecular, Cellular, and Integrative Physiology from University of California, Davis where he studied the role of cardiac ion channel remodeling in heart disease and the potential therapeutic benefits of RNAi medicines. He is the recipient of an HHMI Translational Research Training Grant and author of 16 research publications. He also enjoys teaching and formerly taught Systemic Physiology at California State University of Sacramento.
Full Bio
Section ID:
189583
Class type:
Online Asynchronous.
This course is entirely web-based and to be completed asynchronously between the published course start and end dates. Synchronous attendance is NOT required.
You will have access to your online course on the published start date OR 1 business day after your enrollment is confirmed if you enroll on or after the published start date.
This course is entirely web-based and to be completed asynchronously between the published course start and end dates. Synchronous attendance is NOT required.
You will have access to your online course on the published start date OR 1 business day after your enrollment is confirmed if you enroll on or after the published start date.
Textbooks:
All course materials are included unless otherwise stated.
Policies:
- No refunds after: 6/30/2025
Schedule:
No information available at this time.
Instructor:
Richard Myers, Ph.D.
Richard Myers, Ph.D.
Richard previously worked at Takeda Pharmaceuticals for 9 years within the Gastrointestinal and Inflammation Drug Discovery Unit, advancing novel drug ideas from target ID to clinical candidacy. Richard led multiple drug discovery projects including a small molecule ion channel agonist and a regenerative neuronal cell therapy. In addition to his globally facing project leadership role, Richard led a lab-based pharmacology team in San Diego that supported in vivo, in vitro, and histology studies across the GI & Inflammation portfolio.
Richard earned his Ph.D. in Molecular, Cellular, and Integrative Physiology from University of California, Davis where he studied the role of cardiac ion channel remodeling in heart disease and the potential therapeutic benefits of RNAi medicines. He is the recipient of an HHMI Translational Research Training Grant and author of 16 research publications. He also enjoys teaching and formerly taught Systemic Physiology at California State University of Sacramento.